Genetic Signatures (ASX:GSS) Other Current Receivables: A$-0.01 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genetic Signatures Other Current Receivables?

Genetic Signatures ASX:GSS -1.49% Other Current Receivables is A$-0.01 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Genetic Signatures's Other Current Receivables for the quarter that ended in Dec. 2025 was A$-0.01 Mil.

Genetic Signatures's quarterly Other Current Receivables increased from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.82 Mil) but then stayed the same from Jun. 2025 (A$0.82 Mil) to Dec. 2025 (A$-0.01 Mil).

Genetic Signatures's annual Other Current Receivables increased from Jun. 2023 (A$1.19 Mil) to Jun. 2024 (A$1.26 Mil) but then declined from Jun. 2024 (A$1.26 Mil) to Jun. 2025 (A$0.82 Mil).

Genetic Signatures Other Current Receivables Related Terms

Genetic Signatures Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Genetic Signatures's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Signatures Other Current Receivables Chart

Genetic Signatures Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.23 1.19 1.26 0.82

Genetic Signatures Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 1.26 0.00 0.82 -0.01

Genetic Signatures Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$-0.01 Mil mean?
Genetic Signatures (ASX:GSS) has a Other Current Receivables of A$-0.01 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Genetic Signatures and its competitors.
Is Genetic Signatures' Other Current Receivables too high?
Genetic Signatures' current Other Current Receivables is A$-0.01 Mil.
How does Genetic Signatures' Other Current Receivables compare to TMO and DHR?
Genetic Signatures' Other Current Receivables of A$-0.01 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Genetic Signatures and its competitors. Genetic Signatures's current Other Current Receivables is A$-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current Other Current Receivables is A$-0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current Other Current Receivables is A$-0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genetic Signatures Business Description

Address 7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.